A 58-year-old man presented with a 6-month history of a mildly pruritic rash of the left axilla. The patient was in good health, took no medications, and denied any other symptoms.
A 58-year-old man presented with a 6-month history of a mildly pruritic rash of the left axilla. The patient was in good health, took no medications, and denied any other symptoms.
A solitary, orange-red, slightly scaly and atrophic patch involved the axilla and adjacent skin. The differential diagnosis included tinea corporis, erythrasma, contact dermatitis, parapsoriasis, and mycosis fungoides (cutaneous T-cell lymphoma).
Dr Ted Rosen of Houston writes that a potassium hydroxide evaluation of scale scrapings from a lesion ruled out tinea corporis. Examination of the lesion with a hand-held black light failed to demonstrate the typical coral-red color seen in erythrasma. A skin biopsy disclosed flattened epidermis and a band-like dermal lymphocytic infiltrate that included atypical-appearing cells. Flow cytometry demonstrated clonality of the cells. These findings established the diagnosis of large plaque parapsoriasis. This disorder is considered a precursor of mycosis fungoides, although transformation into cutaneous lymphoma occurs in only about 15% to 20% of patients.
This patient's lesions resolved after a 10-week course of twice-weekly psoralen–UVA therapy. He returns for periodic evaluations.
Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD
June 11th 2025RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.